Antiobesity Medication Semaglutide 2.4 mg Reduced Risk of MACE by 20%: Topline Results from Landmark SELECT TrialAugust 8th 2023ArticleThe reduction in risk of CV events, the first to be shown by an antiobesity drug, was higher than expected and could help alter perceptions of the agents as "lifestyle drugs."

Source: CNN August 12, 2023 10:25 UTC